<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04169867</url>
  </required_header>
  <id_info>
    <org_study_id>MMP</org_study_id>
    <secondary_id>POIR.04.01.02-00-0025/17</secondary_id>
    <nct_id>NCT04169867</nct_id>
  </id_info>
  <brief_title>Polish Microbiome Map</brief_title>
  <official_title>Polish Microbiome Map</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardigen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Institute of Bioorganic Chemistry, Polish Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The National Centre for Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ardigen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Knowledge about the correlations between the composition of the gut microbiome and a wide
      range of diseases has substantially increased in recent years. Nonetheless, there is no
      reference set of information about the microbiome in Poland. The development of such a
      reference will allow polish scientists conducting research in the field of interaction
      between gut flora components and such characteristics as lifestyle, certain diseases or
      patient's responses for treatment. Following the example of such countries as the United
      States, investigators propose to build a unique set of scientific processed information
      describing the variability of the polish population microbiome (Polish Microbiome Map). The
      investigators will provide a reliable dataset that will characterize the gut microbiomes and
      their diversity in the polish population. Additionally, thanks to the creation of the
      standard protocol for microbiome data collection the research conducted by the MMP users will
      be comparable with the information deposited in MMP.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Microbial diversity in stool samples</measure>
    <time_frame>Inclusion</time_frame>
    <description>Microbial DNA - stool samples sequenced by next-generation sequencing platform.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Eating habits and health survey</measure>
    <time_frame>Inclusion</time_frame>
    <description>It includes questions about healthy volunteers' and patients' eating habits that may relate to their health.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1160</enrollment>
  <condition>Melanoma</condition>
  <condition>Healthy Volunteers</condition>
  <condition>Microbiome</condition>
  <condition>Metagenome</condition>
  <condition>Immunotherapy</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <description>This cohort will consist of 1000 healthy volunteers from Poland.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melanoma</arm_group_label>
    <description>This cohort will consist of 160 patients with melanoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Collection of stool samples</intervention_name>
    <description>Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and / or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).</description>
    <arm_group_label>Melanoma</arm_group_label>
    <other_name>Nivolumab</other_name>
    <other_name>Ipilimumab</other_name>
    <other_name>Atezolizumab</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Stool samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy volunteers or oncology patients with primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for Healthy Volunteers group:

          -  Men or women ≥18 years of age

          -  Patients with informed consent to participate in the study.

        Inclusion Criteria for Melanoma group:

          -  Men or women ≥18 years of age

          -  Patients with melanoma

          -  Patients with informed consent to participate in the study.

          -  Patients receiving routine treatment (immunotherapy using anti-PD1 / anti-PDL1 and /
             or anti CTLA4 antibodies), financed by the Polish National Health Fund (NFZ).

          -  The applied immunotherapy should be the first or second line of treatment.

        Exclusion Criteria:

          -  Patients or Healthy Volunteers who are unable to understand, read and / or sign the
             informed consent

          -  Patients or Healthy Volunteers who can not collect stools

          -  Patients with a fecal transplant

          -  The applied immunotherapy is not the first or second line of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Philips, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Institute of Bioorganic Chemistry, Polish Academy of Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Majta</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ardigen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna Philips, PhD</last_name>
    <phone>+48 61 852 89 19</phone>
    <email>gmp.mmp@ibch.poznan.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilia Strycharz-Angrecka</last_name>
    <phone>+48 12 340 94 94</phone>
    <email>emilia.strycharz-angrecka@ardigen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Institute of Bioorganic Chemistry, Polish Academy of Sciences</name>
      <address>
        <city>Poznań</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>gmp.mmp@ibch.poznan.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Melanoma</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Stool samples</keyword>
  <keyword>Cancer</keyword>
  <keyword>Metagenome</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Intestinal microbiota</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>Atezolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

